PD L1 News and Research

RSS

Deciphering the tumor-immune interplay in endometrial carcinoma

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most prevalent gynecological cancers, EC continues to challenge researchers and clinicians due to its dynamic interaction with the immune microenvironment.

11 Mar 2025

Unraveling the genetic differences between LUAD and LUSC in lung cancer

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small cell lung cancer (NSCLC).

8 Mar 2025

Novel treatment approach shows promise for advanced HPV-negative head and neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC).

7 Mar 2025

Study unravels the complex interplay of the UPS in cancer development and treatment

A new review published in Genes & Diseases explores the pivotal role of the ubiquitin-proteasome system (UPS) in regulating the tumor microenvironment (TME) and driving cancer progression. The study provides novel insights into how ubiquitination and deubiquitination impact tumor cells, immune responses, and potential therapeutic strategies for cancer treatment.

24 Feb 2025

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science.

20 Feb 2025

Radiation and immunotherapy help preserve bladders in patients with muscle-invasive bladder cancer

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical trial.

18 Feb 2025

Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for adults with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression level or tumor histology.

14 Feb 2025

New dual-target therapy offers hope for better breast cancer treatment

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in collaboration with Pfizer, have discovered new insights into possible future treatments for breast cancer.

12 Feb 2025

Microbes in your gut could determine cancer treatment outcomes

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, with specific bacterial strains enhancing or inhibiting anti-tumor immunity.

4 Feb 2025

Stanford researchers develop AI model to enhance cancer prognosis predictions

The melding of visual information (microscopic and X-ray images, CT and MRI scans, for example) with text (exam notes, communications between physicians of varying specialties) is a key component of cancer care.

8 Jan 2025

AI-based SCORPIO tool offers better cancer immunotherapy predictions

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of immunotherapy - using only routine blood tests and clinical data.

6 Jan 2025

New nanoparticle platform delivers drug pairs to specific cancer types

Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to specific cancer types, including skin cancer and breast cancer.

23 Dec 2024

Exosomes: A double-edged sword in hepatocellular carcinoma

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance.

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Cancer therapy may raise heart attack and stroke risks by disrupting immune regulation in arteries

Immune checkpoint inhibitors may heighten cardiovascular risks by altering immune interactions in atherosclerotic plaques, particularly in diabetic patients.

4 Dec 2024

Phase 1 study finds serine- and glycine-free diet boosts immune response in colorectal cancer

Findings indicate a serine/glycine-free diet can reduce colorectal cancer growth and enhance immune response, offering insights for immunotherapy strategies.

29 Nov 2024

PD-1 deficiency reveals the impact of checkpoint inhibition on B cell function

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint inhibitors experience increased susceptibility to common infections.

27 Nov 2024

Breakthrough in protein engineering may lead to more effective cancer therapies

Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make a cancer-targeting protein complex more stable, opening doors to better cancer treatments.

15 Nov 2024

Novel bladder cancer treatment gains MHRA approval in the UK

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.

9 Nov 2024

Targeting ferroptosis for overcoming chemoresistance in digestive tract tumors

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant tumors worldwide.

8 Nov 2024